• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    11/8/23 4:31:05 PM ET
    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • Intelligent Bio Solutions (NASDAQ:INBS) stock increased by 33.3% to $0.3 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 979.5K shares, which is 240.8 percent of its average volume over the last 100 days. The company's market cap stands at $1.3 million.
    • Ontrak (NASDAQ:OTRK) stock rose 14.22% to $1.08. The market value of their outstanding shares is at $5.3 million.
    • Panbela Therapeutics (NASDAQ:PBLA) stock increased by 8.99% to $0.73. The market value of their outstanding shares is at $2.1 million.
    • ADMA Biologics (NASDAQ:ADMA) stock moved upwards by 7.73% to $3.9. This security traded at a volume of 140.3K shares come close, making up 6.3% of its average volume over the last 100 days. The company's market cap stands at $877.1 million. The company's, Q3 earnings came out today.
    • LifeMD (NASDAQ:LFMD) shares moved upwards by 7.54% to $7.7. The company's market cap stands at $277.4 million. The company's, Q3 earnings came out today.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) stock increased by 7.52% to $0.57. The market value of their outstanding shares is at $9.3 million. The company's, Q3 earnings came out today.

    Losers

    • Assertio Holdings (NASDAQ:ASRT) stock decreased by 25.8% to $1.58 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 280.3K shares, which is 16.8 percent of its average volume over the last 100 days. The company's market cap stands at $147.1 million. As per the news, the Q3 earnings report came out today.
    • Lucy Scientific Discovery (NASDAQ:LSDI) stock declined by 10.53% to $0.25. The market value of their outstanding shares is at $4.4 million.
    • Omega Therapeutics (NASDAQ:OMGA) shares decreased by 8.99% to $1.62. The company's market cap stands at $89.3 million.
    • Cutera (NASDAQ:CUTR) stock declined by 7.46% to $2.98. Trading volume for this security closed at 61.2K, accounting for 6.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $59.4 million. As per the press release, Q3 earnings came out today.
    • Alzamend Neuro (NASDAQ:ALZN) shares declined by 7.46% to $1.49. The market value of their outstanding shares is at $9.6 million.
    • Bio-Path Hldgs (NASDAQ:BPTH) stock decreased by 6.56% to $0.51. The company's market cap stands at $5.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $ADMA
    $ALZN
    $ASRT

    CompanyDatePrice TargetRatingAnalyst
    Assertio Holdings Inc.
    $ASRT
    4/9/2026$18.00Buy → Neutral
    H.C. Wainwright
    ADMA Biologics Inc
    $ADMA
    3/26/2026Overweight → Neutral
    Cantor Fitzgerald
    LifeMD Inc.
    $LFMD
    3/16/2026$8.00Neutral → Outperform
    Mizuho
    LifeMD Inc.
    $LFMD
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    LifeMD Inc.
    $LFMD
    12/10/2024$12.00Buy
    Lake Street
    LifeMD Inc.
    $LFMD
    12/4/2024$7.00Neutral
    Mizuho
    Omega Therapeutics Inc.
    $OMGA
    11/15/2024Outperform → Mkt Perform
    Raymond James
    LifeMD Inc.
    $LFMD
    8/23/2024$11.00Buy
    B. Riley Securities
    More analyst ratings

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Assertio Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Assertio Therapeutics from Buy to Neutral and set a new price target of $18.00

    4/9/26 8:30:00 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADMA Biologics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral

    3/26/26 8:39:56 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LifeMD upgraded by Mizuho with a new price target

    Mizuho upgraded LifeMD from Neutral to Outperform and set a new price target of $8.00

    3/16/26 8:33:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    SEC Filings

    View All

    SEC Form SC14D9C filed by Assertio Holdings Inc.

    SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)

    4/9/26 5:24:04 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC TO-C filed by Assertio Holdings Inc.

    SC TO-C - Assertio Holdings, Inc. (0001808665) (Subject)

    4/9/26 5:16:11 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Assertio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K/A - Assertio Holdings, Inc. (0001808665) (Filer)

    4/9/26 5:15:20 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Elms Steve bought $217,420 worth of shares (14,000 units at $15.53) (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    3/9/26 9:14:42 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Horne William B. bought $3,285 worth of shares (3,334 units at $0.99), increasing direct ownership by 13% to 30,000 units (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    3/27/25 7:30:10 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ault Milton C Iii bought $2,969 worth of shares (2,905 units at $1.02) (SEC Form 4)

    4 - Alzamend Neuro, Inc. (0001677077) (Issuer)

    3/25/25 4:30:07 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

    NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems. Foundayo is available to eligible LifeMD patients through the Company's integration with LillyDirect®, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is $149 per month for the initial dosage. Patients with eligible commer

    4/10/26 8:15:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio

    -- Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence -- -- SYMPAZAN® Establishes a Neurology Rare Disease Footprint within Cosette -- -- Additional Brands include INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® -- Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (NASDAQ:ASRT). The acquisition expands Cosette's branded portfolio and adds the U.S. rights to SYMPAZAN®, a growing, patent-protected asset, further advanc

    4/8/26 4:10:00 PM ET
    $ASRT
    $HLNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Assertio Announces Agreement to be Acquired by Garda Therapeutics

    All-Cash Tender Offer of $18 per share – or $125.1 Million – Plus Contingent Value Right Tender Offer Price Represents 34.6% Premium to Unaffected Price and 46.6% Premium to Unaffected 30-day Volume-Weighted Average Price Transaction Follows Comprehensive Strategic Review Process Initiated in First Quarter of 2025 Includes Additional "Shop" Period to Ensure Maximum Value for Shareholders Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced a definitive agreement (the "Garda Agreement") to be acquired by Garda Therapeutics ("Garda" or the "Buyer") for $18 per share in cash, or a total cash consideration of $125.1 million, (the "Garda Transaction"), plu

    4/8/26 4:04:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kestenberg-Messina Kaitlin M.

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    4/3/26 9:00:32 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Pisano Christopher A

    4 - LifeMD, Inc. (0000948320) (Issuer)

    4/1/26 5:33:43 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Pisano Christopher A

    3 - LifeMD, Inc. (0000948320) (Issuer)

    4/1/26 5:32:25 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

    NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition. "We are thrilled to welcome Atul to LifeMD," said Justin Schreiber, Chairman and CEO of LifeMD. "He is a versatile financial leader who has spent nearly three decades helping healthcare and technology companies scale, and h

    3/16/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previo

    2/25/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LifeMD Names COO and Promotes Two Executives

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD's growth, most recently serving as Senior Vice President of Operations. "Shayna's proven track record of building and managing an industry-leading operations team and infrastructure in a complex and rapidly growing environment makes her the ideal leader to step into the role of COO," said Justin Schreiber, Chairman and Chief Executive Officer of L

    7/31/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Financials

    Live finance-specific insights

    View All

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's hea

    3/24/26 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    Assertio Holdings, Inc. ("Assertio") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wis

    3/3/26 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy ser

    2/23/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    $ACRX
    $ADMA
    $ALZN
    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care